RSD1235

DRUG3 trials

Sponsors

Astellas Pharma Inc

Conditions

Atrial FibrillationAtrial Flutter

Phase 3

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

CompletedNCT00115791

Astellas Pharma IncAtrial Fibrillation, Atrial Flutter

Start: 2004-06-30End: 2005-06-30Updated: 2008-04-01

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

CompletedNCT00125320

Astellas Pharma IncAtrial Fibrillation, Atrial Flutter

Start: 2004-06-30End: 2007-02-28Updated: 2007-12-24

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

CompletedNCT00281554

Astellas Pharma IncAtrial Fibrillation

Start: 2005-10-31End: 2007-01-31Updated: 2008-04-03

Related Papers

A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.

2010-06-0160 citations

Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.

2009-12-01127 citations